The way clinical trials are monitored is once again about to change.
This isn’t the first time clinical trial monitoring has evolved. Over the past three decades, the industry has undergone two major transformations in how monitoring is performed.
For much of the 1990s and early 2000s, monitoring relied on frequent on-site visits and extensive source data verification (SDV), with many studies aiming to verify nearly every data point. While rigorous in intent, this approach became increasingly difficult to sustain as trials grew larger and more complex, delivering diminishing returns relative to its cost and operational burden.
The industry responded by adopting risk-based monitoring (RBM) and centralized monitoring, shifting from exhaustive verification to a targeted, data-driven approach focused on the risks that mattered most. This evolution was reinforced by FDA and EMA guidance and ultimately codified in ICH E6(R2) in 2016.
While RBM improved efficiency and data quality, it did not fundamentally change how monitoring work was performed. CRAs still spent much of their time manually reviewing data, reconciling information across systems, documenting findings, and coordinating follow-up activities.
We are now entering a third shift. Unlike the first two, which primarily redistributed how monitoring effort was allocated, this one fundamentally changes the old rules on who and what is monitoring trial performance.
The persistent inefficiency problem
Despite decades of process innovation, clinical monitoring remains a high-friction discipline. CRAs spend a disproportionate share of their working hours on administrative activities. This includes aggregating data from disparate source systems, reconciling discrepancies, scheduling and documenting site interactions, and escalating protocol deviations through organizational chains that move slower than the underlying risk.
This inefficiency is not a failure of personnel. Instead it’s a failure of systemic tools and workflows surrounding them not being able to keep up with the volume, velocity, or heterogeneity of modern trial data. The result is that CRAs greatest strength, their expert judgement, is consistently crowded out by the aforementioned volume of administrative work.
Agentic AI as operational infrastructure
Agentic AI refers to AI systems capable of autonomous, goal-directed action across multi-step workflows. They are, in a sense, systems that can perceive context, reason about it, and execute sequences of tasks without human intervention at each node. In the context of clinical monitoring, this capability has very practical implications.
Clinical monitoring agents are designed to assume the tactical burden that currently consumes CRA capacity. By autonomously handling continuous data surveillance, signal detection, automated issue triage, pre-visit preparation, documentation at a pace and scale that no human can match, agentic AI redefines the role of a CRA. The primary outcome of this redefinition enables a wider monitoring footprint, higher-value site interactions, and earlier signal detection.
This inefficiency is not a failure of personnel. Instead, it is a failure of the systemic tools and workflows surrounding them, which have not been able to keep up with the volume, velocity, or heterogeneity of modern trial data. Enter a new technology, one that was not possible before, that can finally unburden the CRA and close that gap.
Upgrading the CRA role with agentic AI
A common and understandable concern when AI automation enters a professional domain is displacement. In clinical monitoring, the outcome of implementing agentic AI is not displacement, but an upleveling of the core responsibilities.
This is because the tasks that agents handle best (data aggregation, discrepancy flagging, scheduling logistics) are the ones that have pulled CRAs away from monitoring and oversight. With those automated, what’s left for the CRA is the core value of what they do, exercising their clinical judgement, managing site relationships, interpreting risk, and keeping trials on track. In this sense, the role of a CRA is upleveled, not displaced.
The operational implication is significant. When tactical burden is removed from a CRA's workload, two things occur simultaneously. The first is that monitoring capacity expands as the same CRA can effectively oversee a larger site portfolio. The second is that the quality of each site interaction improves as the CRA arrives prepared, contextually informed, and focused on high-leverage engagement rather than administrative catch-up.
However, there are even more benefits in the ability of these efficiencies to compound.
How agentic AI unlocks study-level and portfolio-level compounding effects
The value of agentic monitoring does not accrue only at the individual CRA level. At the study level, proactive and continuous oversight enables earlier identification of enrollment risk, data quality deterioration, and protocol deviation patterns. These are problems that, when detected late, impose costs measured in months and millions. The compression of key milestones, from enrollment completion to database lock, is a direct downstream consequence of this earlier signal detection capability.
This value compounds across three layers. The first is operational throughput. Back-office work, including email drafting, visit prep, query handling, reconciliation, and cross-system lookups, is compressed immediately, giving hours back to the CRA from week one.
The second is critical path compression. Earlier enrollment signals, cleaner data flowing into lock, and faster amendment execution move every gate on the critical path sooner, translating into weeks back on the trial.
The third plays out across a sponsor's full portfolio, where these gains compound further. Liberated CRA capacity can be redeployed rather than supplemented with headcount, supporting more sites per CRA and fewer, shorter on-site visits. Reduced travel intensity lowers operational spend. Lower burnout and turnover rates are a persistent challenge in monitoring-intensive roles, and removing them often improves institutional continuity and site relationship quality, building a fleet that can absorb more studies.
The efficiency gains at the study level stack into structural advantages at the program and portfolio level. This means faster timelines, cleaner data, and a retained talent base capable of executing with consistency across therapeutic areas.
Conclusion: Give CRAs the tools to push trials forward, faster
Technology adoption curves in clinical operations have historically been gradual. The sponsors and CROs that moved earliest on electronic data capture, risk-based monitoring, and decentralized trial design accrued durable operational advantages. This is not merely because the tools were better, but because early adoption built organizational fluency that later adopters had to acquire under competitive pressure.
The same dynamic applies here. Organizations that deploy agentic monitoring infrastructure now are not simply accessing a more efficient tool. They are building the operational muscle memory, the data infrastructure, and the institutional capability that will compound over time. Those that delay will find themselves acquiring that capability at greater cost, against a steeper learning curve, in a landscape where their competitors have already optimized.
The third shift in clinical monitoring is underway. The question for every sponsor, CRO, and site network is not whether to participate in it, but when, and at what position on the adoption curve, they choose to do so.
